Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Arthritis, Rheumatoid 8Psoriasis 7Lymphoma, Follicular 4Leukemia 4Myelodysplastic Syndromes 3Asthma 3Vasculitis 2Respiratory Distress Syndrome 2Recurrence 2Pneumonia 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Inflammation 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Arthritis, Psoriatic 2Arthritis, Juvenile 2Wilms Tumor 1Uveitis 1Temporomandibular Joint Disorders 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1Pancreatic Neoplasms 1Neuroblastoma 1Neoplasms 1Metabolic Syndrome 1

Interventions

Dexamethasone 12Melphalan 7Calcium Dobesilate 6Lenalidomide 5Bortezomib 5Cyclophosphamide 4miridesap 3ixazomib 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2pomalidomide 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1birtamimab 1auricularum 1Vinorelbine 1Thalidomide 1Tacrolimus 1Pharmaceutical Preparations 1Interleukin-2 1Granulocyte-Macrophage Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Etanercept 1Drug Evaluation 1Blood Specimen Collection 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Amyloidosis × Etanercept × Clear all
NCT00224393 2023-05-30

Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis

The Cleveland Clinic

Phase 2 Completed
60 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡